Cardiovascular News Round-up

October 2007
PharmaWatch: Monthly Review;Oct2007, Vol. 6 Issue 10, p10
Market Research Report
The article offers news briefs related to the pharmaceutical industry. Merck & Co. Inc. has completed the acquisition of NovaCardia Inc., a privately held clinical-stage pharmaceutical company focused on cardiovascular disease. Meanwhile, Sanofi Aventis SA has announced that one-year findings from two studies evaluating Lovenox confirm clear net clinical benefit for patients with acute ST-segment elevation myocardial infarction compared to unfractionnated heparin.


Related Articles

  • Sanofi-aventis (s-a)/Merck & Co.  // Agri Marketing;Apr2010, Vol. 48 Issue 3, p10 

    The article reports on the announcement of the Merial-Intervet/Schering-Plough merger that was exercised by Sanofi-Aventis SA and Merck & Co. Inc.

  • Merial-Intervet/Schering Plough merger collapse.  // Irish Farmers Monthly;Apr2011, p6 

    The article reports on the announcement of Sanofi-Aventus SA and Merck and Co. Inc. that their plans to merge their animal health divisions have been terminated due to the complexity of implementing the merger and the regulatory review process.

  • Merck and Lundbeck: Sanofi set to benefit from drug failure.  // PharmaWatch: CNS;May2007, Vol. 6 Issue 5, p9 

    The article reports on the impact of the negative result of the phase III data for gaboxadol manufactured by Merck & Co. Inc. and Lundbeck on the market leader Sanofi-Aventis. Sanofi's drug Ambien will not face considerable competition from a Merck marketed alternative. The market for...

  • The Industry.  // Pharmaceutical Representative;Oct2007, Vol. 37 Issue 10, p10 

    The article offers news briefs related to pharmaceutical industry. Merck & Co. Inc. has agreed to acquire San Diego-based NovaCardia Inc. Cell Therapeutics Inc. is buying U.S. marketing, sales and development rights to Biogen Idec's Zevalin. Watson Pharmaceuticals Inc. and Depomed Inc. have...

  • Merck sets science in motion. Arnold, Matthew // Medical Marketing & Media;Jan2008, Vol. 43 Issue 1, p40 

    The article provides information about Merck & Co. Inc., a pharmaceutical company which won the "Medical Marketing and Media's (MM&M)" Company of the Year Award in 2007. According to some officials, the key to Merck's transformation was an organizational shake-up which brought the scientific and...

  • LMWH gets another indication OK'd.  // Drug Topics;6/4/2007, Vol. 151 Issue 11, p8 

    The article reports that drug manufacturer Sanofi-Aventis SA has improved the drug indication of its low molecular weight heparin, enoxaparin, for the treatment of patients with acute ST-segment elevation myocardial infarction (STEMI). The drug was approved based on the results of the...

  • Relypsa Stock Jumps On Buyout Rumors. AMY REEVES // Investors Business Daily;12/4/2015, p00 

    The article focuses on the increase in the stocks of biotechnology company Relypsa (RLYP) on December 4, 2015 while buyout rumors spread. Topics discussed include offer of industrial services and equipment Merck & Co. Inc. to RLYP, potential bidders for the company, such as pharmaceutical...

  • Buyout Value Debate Goes on Despite 5-Year Campath Data. Boggs, Jennifer // BioWorld Today;10/15/2010, Vol. 21 Issue 200, p1 

    The article reports that Sanofi-Aventis SA has declined to increase its 69 U.S. dollar-per-share bid to acquire Genzyme Corp. despite a promising five-year data from Genzyme Corp.'s Phase II extension study of alemtuzumab in relapsing-remitting multiple sclerosis (MS). Sanofi went hostile after...

  • CORPORATE.  // MondayMorning;6/1/2009, Vol. 17 Issue 20, p2 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics